Magnetic Nanoparticle-Based Hyperthermia Mediates Drug Delivery and Impairs the Tumorigenic Capacity of Quiescent Colorectal Cancer Stem Cells.
cancer stem cells
colorectal cancer
doxorubicin
magnetic hyperthermia
magnetic nanoparticles
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
14 Apr 2021
14 Apr 2021
Historique:
pubmed:
3
4
2021
medline:
11
8
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
Cancer stem cells (CSCs) are the tumor cell subpopulation responsible for resistance to chemotherapy, tumor recurrence, and metastasis. An efficient therapy must act on low proliferating quiescent-CSCs (q-CSCs). We here investigate the effect of magnetic hyperthermia (MHT) in combination with local chemotherapy as a dual therapy to inhibit patient-derived colorectal qCR-CSCs. We apply iron oxide nanocubes as MHT heat mediators, coated with a thermoresponsive polymer (TR-Cubes) and loaded with DOXO (TR-DOXO) as a chemotherapeutic agent. The thermoresponsive polymer releases DOXO only at a temperature above 44 °C. In colony-forming assays, the cells exposed to TR-Cubes with MHT reveal that qCR-CSCs struggle to survive the heat damage and, with a due delay, restart the division of dormant cells. The eradication of qCR-CSCs with a complete stop of the colony formation was achieved only with TR-DOXO when exposed to MHT. The
Identifiants
pubmed: 33797220
doi: 10.1021/acsami.0c21349
pmc: PMC8045020
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Magnetite Nanoparticles
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15959-15972Références
Int J Hyperthermia. 2002 Jul-Aug;18(4):267-84
pubmed: 12079583
Mol Aspects Med. 2014 Oct;39:61-81
pubmed: 23927966
Expert Opin Biol Ther. 2017 Mar;17(3):313-324
pubmed: 27960589
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
ACS Nano. 2012 Apr 24;6(4):3080-91
pubmed: 22494015
Oncotarget. 2013 Jul;4(7):950-1
pubmed: 23807730
Nat Rev Drug Discov. 2015 Mar;14(3):165
pubmed: 25722238
ACS Nano. 2014 May 27;8(5):4268-83
pubmed: 24738788
Biomaterials. 2012 Apr;33(10):2961-70
pubmed: 22245557
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Lancet Oncol. 2010 Jun;11(6):561-70
pubmed: 20434400
Nat Rev Urol. 2012 Oct;9(10):583-94
pubmed: 22890301
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Oncol Lett. 2018 Mar;15(3):3091-3099
pubmed: 29435042
Gastroenterology. 2011 Jan;140(1):297-309
pubmed: 20951698
Mol Pharm. 2013 Apr 1;10(4):1432-41
pubmed: 23432410
Oncotarget. 2016 Jun 14;7(24):35894-35916
pubmed: 27145285
World J Stem Cells. 2018 Dec 26;10(12):183-195
pubmed: 30613312
Cell Stem Cell. 2014 Mar 6;14(3):342-56
pubmed: 24607406
J Neurooncol. 2011 Jun;103(2):317-24
pubmed: 20845061
Theranostics. 2020 Jan 1;10(3):1181-1196
pubmed: 31938059
Biomed Pharmacother. 2019 Oct;118:109323
pubmed: 31400669
Acc Chem Res. 2018 May 15;51(5):999-1013
pubmed: 29733199
Cell. 2010 Jan 8;140(1):62-73
pubmed: 20074520
Nat Rev Cancer. 2013 Oct;13(10):727-38
pubmed: 24060864
Oncol Lett. 2012 Aug;4(2):187-193
pubmed: 22844351
PLoS One. 2012;7(8):e43379
pubmed: 22927961
Ann Oncol. 2002 Aug;13(8):1173-84
pubmed: 12181239
Front Cell Dev Biol. 2019 Feb 18;7:16
pubmed: 30834247
Sci Transl Med. 2010 Oct 27;2(55):55ra79
pubmed: 20980696
Stem Cells Int. 2016;2016:1740936
pubmed: 27418931
Mol Imaging Biol. 2016 Aug;18(4):617-26
pubmed: 26630973
Cell Stem Cell. 2007 Oct 11;1(4):389-402
pubmed: 18371377
Int J Hyperthermia. 2017 Jun;33(4):419-427
pubmed: 28100096
Nature. 2013 Sep 19;501(7467):328-37
pubmed: 24048065
ACS Appl Mater Interfaces. 2019 Feb 13;11(6):5727-5739
pubmed: 30624889